Neuren Pharmaceuticals shares an update on the the company's Angelman Syndrome Clinical Study. July 8, 2023
- Forums
- ASX - By Stock
- NEU
- Ann: Neuren commences Phase 2 trial of NNZ-2591 in Angelman
Ann: Neuren commences Phase 2 trial of NNZ-2591 in Angelman, page-18
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$13.80 |
Change
-0.120(0.86%) |
Mkt cap ! $1.744B |
Open | High | Low | Value | Volume |
$13.94 | $13.96 | $13.50 | $2.991M | 218.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 165 | $13.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.80 | 613 | 18 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 89 | 13.790 |
8 | 533 | 13.780 |
6 | 364 | 13.770 |
8 | 811 | 13.760 |
6 | 1838 | 13.750 |
Price($) | Vol. | No. |
---|---|---|
13.800 | 505 | 16 |
13.810 | 631 | 9 |
13.820 | 859 | 11 |
13.830 | 742 | 13 |
13.840 | 868 | 7 |
Last trade - 13.27pm 06/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |